目的 探討血必凈注射液聯(lián)合氯解磷定注射液治療有機(jī)磷農(nóng)藥中毒的臨床療效。方法 選取2012年3月—2016年3月商丘市第一人民醫(yī)院收治的有機(jī)磷農(nóng)藥中毒患者82例，根據(jù)治療方案的不同分為對(duì)照組（36例）和治療組（46例）。對(duì)照組足量應(yīng)用氯解磷定注射液，用藥間隔時(shí)間為2～4 h，在膽堿酯酶活力≥60%正常值后停藥。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注血必凈注射液，50 mL加入生理鹽水100 mL，1 次/d。兩組患者均持續(xù)治療7 d。觀察記錄兩組患者存活情況、中間綜合征和膽堿酯酶恢復(fù)時(shí)間及肌酸激酶同工酶（CK-MB）和肌鈣蛋白T（CTnT）變化。結(jié)果 治療后，治療組死亡病例存活時(shí)間顯著長于對(duì)照組，住院時(shí)間顯著短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，治療組中間綜合征發(fā)生率和膽堿酯酶恢復(fù)正常時(shí)間均顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義。治療后，兩組患者CK-MB和CTnT均顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組患者CK-MB和CTnT比對(duì)照組更低，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 血必凈注射液聯(lián)合氯解磷定注射液治療有機(jī)磷農(nóng)藥中毒可降低中間綜合征發(fā)生率和膽堿酯酶恢復(fù)正常時(shí)間，具有更好的心肌保護(hù)作用，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical effect of Xuebijing Injection combined with Pralidoxime Chloride Injection in treatment of organophosphorus pesticide poisoning. Methods Patients (82 cases) with organophosphorus pesticide poisoning in the First People's Hospital of Shangqiu from March 2012 to March 2016 were divided into control (36 cases) and treatment (46 cases) groups according to different treatment. Patients in the control group were iv administered with Pralidoxime Chloride Injection adequately, the time of dosing interval was 2-4 h, discontinue medication was administered after ChE ≥ 60% of the normal value. Patients in the treatment group were iv administered with Xuebijing Injection on the basis of the control group, 50 mL added into normal saline 100mL, once daily. Patients in two groups were treated for 7 d. After treatment, survival situation, intermediate syndrome, holinesterase recovery time, CK-MB and CTnT in two groups before and after treatment were compared. Results After treatment, the survival time of death case in the treatment group was significantly longer than that in the control group, also hospital stay was significantly shorter than that in the control group, and there were differences between two groups (P < 0.05). After treatment, the incidence rate of intermediate syndrome and holinesterase recovery time in the treatment group was significantly lower than those in the control group, and there were differences between two groups (P < 0.05). After treatment, the CK-MB and CTnT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). The CK-MB and CTnT in treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xuebijing Injection combined with Pralidoxime Chloride Injection can reduce the incidence of intermediate syndrome and holinesterase recovery time with better myocardial protection, which has a certain clinical application value.